Safety and low molecular weight heparin in older people in a hospital with ambulatory care

被引:2
|
作者
Chan, Daniel K. Y.
Ong, Bin
Almafragy, Hamid
Karr, Margaret
Hung, Arthur W. T.
Liu, Jun G.
机构
[1] Univ New S Wales, Dept Aged Care & Rehabil, Bankstown Lidcombe Hosp, Bankstown, NSW 2200, Australia
[2] Bankstown Lidcombe Hosp, Dept Ambulatory Care, Bankstown, NSW 2200, Australia
[3] BreastScreen NSW, State Coordinat Unit, Parramatta, BC 2150, Canada
关键词
low molecular weight heparin; bleeding; age >= 70; ambulatory care;
D O I
10.1016/j.archger.2005.10.011
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
To examine major bleeding and mortality rates of low molecular weight heparin (LMWH) and unfractionated heparin (UFH) for patients with pulmonary embolism (PE) and/or deep vein thrombosis (DVT), a retrospective review of the medical records for 286 patients who presented at a local hospital with PE and/or DVT during the period November 2002-August 2003 was performed. Data collected: presence of co-morbidities, concurrent medications, presence, site and severity of bleeding, outcome. Of all the patients, 50.7% received LMWH plus warfarin, 21.0% received UFH plus LMWH plus warfarin, 14.0% received UFH and warfarin, and 9.8% received LMWH only. There were nine minor bleeds and six major bleeds, which resulted in four deaths. Being a hospitalized patient and being age >= 70 years were associated with a major bleed (p < 0.05). For hospital inpatients age >= 70 years on UFH and LMWH the number of major bleeds/1000 patient days was 18.9 and 9.2, respectively. The major bleeding rate is comparable if not better than that reported in the literature in our hospital setting where nearly half of the anticoagulation services were provided as ambulatory care. The increased rate of bleeding in the elderly we found is consistent with the findings of previous studies. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:233 / 241
页数:9
相关论文
共 50 条
  • [21] Heparin and low molecular weight heparin: background and pharmacology
    Morris, TA
    CLINICS IN CHEST MEDICINE, 2003, 24 (01) : 39 - +
  • [22] Quality control, safety assessment and preparation approaches of low molecular weight heparin
    Yu, Yanlei
    Song, Yue
    Zhao, Yunjie
    Wang, Ningning
    Wei, Bin
    Linhardt, Robert J.
    Dordick, Jonathan S.
    Zhang, Fuming
    Wang, Hong
    CARBOHYDRATE POLYMERS, 2024, 339
  • [23] Evaluating the Safety of Low Molecular Weight Heparin for Thromboprophylaxis in Traumatic Brain Injury
    Haider, Ansab A.
    Prabhakaran, Kartik
    Azim, Asad
    Con, Jorge
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2019, 229 (04) : E228 - E229
  • [24] Safety and efficacy of low molecular weight heparin (enoxaparin): A pediatric experience.
    Punzalan, RC
    Hillery, CA
    Montgomery, RR
    Scott, JP
    Gil, JC
    BLOOD, 1997, 90 (10) : 1310 - 1310
  • [25] Efficacy and safety of low-molecular-weight-heparin during pregnancy.
    Andersen, Anita Sylvest
    Berthelsen, Joergen G.
    BLOOD, 2006, 108 (11) : 266A - 266A
  • [26] Low molecular weight heparin and epidurals
    Crews, JC
    JOURNAL OF CLINICAL MONITORING AND COMPUTING, 1998, 14 (7-8) : 507 - 509
  • [27] Is low molecular weight heparin a neuroprotectant?
    Jonas, S
    Sugimori, M
    Llinas, R
    NEUROPROTECTIVE AGENTS - THIRD INTERNATIONAL CONFERENCE, 1997, 825 : 389 - 393
  • [28] LOW-MOLECULAR-WEIGHT HEPARIN
    WOLF, H
    MEDICAL CLINICS OF NORTH AMERICA, 1994, 78 (03) : 733 - 743
  • [29] Low molecular weight heparin in children
    Albisetti, M
    Andrew, M
    EUROPEAN JOURNAL OF PEDIATRICS, 2002, 161 (02) : 71 - 77
  • [30] LOW-MOLECULAR-WEIGHT HEPARIN
    HIRSH, J
    LEVINE, MN
    BLOOD, 1992, 79 (01) : 1 - 17